JUN 18, 2016 11:29 AM PDT

FDA Approves At-Home Stomach Pump for Obesity Treatment

WRITTEN BY: Xuan Pham
The U.S. Food and Drug Administration just approved a new line of treatment for obese patients who struggle with the conventional non-surgerical weight-loss therapy. The newly approved device, named AspireAssist, involves a tube connected to the stomach that will drain a small amount of digested food after every meal. In effect, the device resembles a carefully controlled stomach pump, which has incited fierce criticisms amongst health experts.
   AspireAssist
 "The AspireAssist approach helps provide effective control of calorie absorption, which is a key principle of weight management therapy," said William Maisel, deputy director for science and chief scientist in the FDA's Center for Devices and Radiological Health.
 
Indeed, the AspireAssist’s success is through preventing the body from absorbing 100 percent of the foods the patient ingests. It starts with the surgeon placing a tube in the stomach. Connected to this tube is a port valve that’s flushed against the abdomen, on the outside of the body. Then after every meal, the patient drains out part of the stomach’s contents via an external connector to the port valve.
 
In clinical trials, the device demonstrated a 30 percent reduction in the calories absorbed by patients. Furthermore, of the 111 patients treated with AspireAssist, the average weight loss was 12.1 percent of their total body weight. This is significantly higher than the 3.6 percent lost in the control group who only received lifestyle therapy.
 
To help patients stay on track and prevent abuse of the device, makers have put safety mechanisms in place. For example, the device is programmed to stop working after 115 cycles, which equates to about 5 to 6 weeks of therapy. This means that doctors are closely monitoring patients to ensure proper use. In addition, this safety measure makes sure that the device is checked frequently for infections and other complications.
 
Nevertheless, it’s not enough to just be outfitted with the AspireAssist device. For patients to achieve healthy weight loss and maintain their progress, physicians agree that counseling and behavioral therapies are not optional. "Patients need to be regularly monitored by their health care provider and should follow a lifestyle program to help them develop healthier eating habits and reduce their calorie intake," said Maisel.
 
Not everyone who desires weight loss will be eligible for the AspireAssist. The device is only intended to help those who are over 22 years old, and are clinically obese, as defined by having a body mass index of 35 to 55. They must also have demonstrated history of failed weight loss via conventional methods that didn’t involve surgery.
 
Of course, as with any surgical procedure, the AspireAssist is not without risks. But for patients who need this help, doctors and the FDA agree that the benefits of weight loss exceed the risks of the procedure. However, critics of the device have gone as far as calling this a “bulimia machine” and wondered whether an at-home stomach pump is actually going a step too far.

Additional source: FDA release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
MAY 20, 2021
Clinical & Molecular DX
Gonorrhea Testing on the Go
MAY 20, 2021
Gonorrhea Testing on the Go
Forget lab-based tests—a new portable microfluidic device links to a mobile app, diagnosing gonorrhea in just 15 m ...
MAY 24, 2021
Clinical & Molecular DX
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
MAY 24, 2021
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
Over 1.5 billion vaccine doses have been administered worldwide, but SARS-CoV-2 variants are now threatening efforts to ...
JUN 01, 2021
Genetics & Genomics
Sequencing and Identifying SARS-CoV-2 Variants Efficiently
JUN 01, 2021
Sequencing and Identifying SARS-CoV-2 Variants Efficiently
  Viral surveillance can give researchers vital information about virus origins, transmission routes, affected popu ...
JUL 15, 2021
Clinical & Molecular DX
Childhood Lead Exposure Influences Personality in Adulthood
JUL 15, 2021
Childhood Lead Exposure Influences Personality in Adulthood
Exposure to toxic chemicals in childhood could have unlikely effects on personality, and behavioral traits in adulthood, ...
AUG 19, 2021
Cancer
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
AUG 19, 2021
Vitamin D Reduces Risk of Early-Onset Colorectal Cancer
Colorectal cancer (CRC) is the third most diagnosed type of cancer in both men and women in the United States and CRC in ...
SEP 07, 2021
Clinical & Molecular DX
Dogs Can Pick Up the 'Seizure Smell', Alert Their Owners
SEP 07, 2021
Dogs Can Pick Up the 'Seizure Smell', Alert Their Owners
Dogs offer so much more than companionship and unconditional love. New research shows that for patients with epilepsy, t ...
Loading Comments...